CN101415721A - 用于纯化和结晶目的分子的组合物 - Google Patents

用于纯化和结晶目的分子的组合物 Download PDF

Info

Publication number
CN101415721A
CN101415721A CNA2004800263533A CN200480026353A CN101415721A CN 101415721 A CN101415721 A CN 101415721A CN A2004800263533 A CNA2004800263533 A CN A2004800263533A CN 200480026353 A CN200480026353 A CN 200480026353A CN 101415721 A CN101415721 A CN 101415721A
Authority
CN
China
Prior art keywords
molecule
coordination
composition
ligand
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800263533A
Other languages
English (en)
Chinese (zh)
Inventor
G·帕特科尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affisink Biotechnology Ltd
Original Assignee
Affisink Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affisink Biotechnology Ltd filed Critical Affisink Biotechnology Ltd
Publication of CN101415721A publication Critical patent/CN101415721A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNA2004800263533A 2003-07-24 2004-07-22 用于纯化和结晶目的分子的组合物 Pending CN101415721A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL15708603A IL157086A0 (en) 2003-07-24 2003-07-24 Multivalent ligand complexes
IL157086 2003-07-24

Publications (1)

Publication Number Publication Date
CN101415721A true CN101415721A (zh) 2009-04-22

Family

ID=32652285

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800263533A Pending CN101415721A (zh) 2003-07-24 2004-07-22 用于纯化和结晶目的分子的组合物

Country Status (13)

Country Link
US (1) US20060121519A1 (cg-RX-API-DMAC7.html)
EP (1) EP1648995A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007515384A (cg-RX-API-DMAC7.html)
KR (1) KR20060037337A (cg-RX-API-DMAC7.html)
CN (1) CN101415721A (cg-RX-API-DMAC7.html)
CA (1) CA2531492A1 (cg-RX-API-DMAC7.html)
IL (2) IL157086A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06000944A (cg-RX-API-DMAC7.html)
NO (1) NO20060400L (cg-RX-API-DMAC7.html)
RU (1) RU2006105648A (cg-RX-API-DMAC7.html)
SG (1) SG145760A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005010141A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200600315B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7956165B2 (en) 2003-07-24 2011-06-07 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest
WO2006085321A2 (en) * 2005-02-10 2006-08-17 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8163886B2 (en) * 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2009064425A1 (en) * 2007-11-13 2009-05-22 Rational Affinity Devices, L.L.C. Multistate affinity ligands for the separation and purification of antibodies, antibody fragments and conjugates of antibodies and antibody fragments
CA2708836A1 (en) * 2007-12-17 2009-06-25 Affisink Biotechnology Ltd. Methods for purifying or depleting molecules or cells of interest
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
DK2370561T3 (da) 2008-12-16 2019-10-21 Emd Millipore Corp Omrøringstankreaktor og fremgangsmåde
KR101855714B1 (ko) 2010-03-05 2018-05-10 베링거 인겔하임 인터내셔날 게엠베하 항체의 선택적 농축
CN102892791B (zh) 2010-05-17 2017-05-17 Emd密理博公司 用于纯化生物分子的刺激响应性聚合物
US10030224B2 (en) 2015-11-01 2018-07-24 Ariel-University Research And Development Company Ltd. Methods of analyzing cell membranes
WO2021152584A1 (en) 2020-01-28 2021-08-05 Ariel Scientific Innovations Ltd. Methods of analyzing cell membranes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) * 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5215927A (en) * 1986-01-30 1993-06-01 Fred Hutchinson Cancer Research Center Method for immunoselection of cells using avidin and biotin
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6740734B1 (en) * 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6017719A (en) * 1994-06-14 2000-01-25 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
US20010008766A1 (en) * 1998-03-17 2001-07-19 Sylvia Daunert Quantitative binding assays using green fluorescent protein as a label
US6589503B1 (en) * 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US7198930B2 (en) * 2000-02-29 2007-04-03 Millennium Pharmaceuticals, Inc. Human protein kinase, phosphatase, and protease family members and uses thereof
JP5398945B2 (ja) * 2001-04-23 2014-01-29 マリンクロッド エルエルシー TcおよびRe標識放射活性グリコシル化オクトレオチド誘導体
US20040265921A1 (en) * 2003-06-30 2004-12-30 National University Of Singapore Intein-mediated attachment of ligands to proteins for immobilization onto a support
US7956165B2 (en) * 2003-07-24 2011-06-07 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest

Also Published As

Publication number Publication date
IL157086A0 (en) 2004-02-08
US20060121519A1 (en) 2006-06-08
JP2007515384A (ja) 2007-06-14
KR20060037337A (ko) 2006-05-03
WO2005010141A3 (en) 2009-03-26
SG145760A1 (en) 2008-09-29
ZA200600315B (en) 2007-04-25
EP1648995A4 (en) 2010-03-10
IL173107A0 (en) 2006-06-11
RU2006105648A (ru) 2006-07-27
MXPA06000944A (es) 2006-03-30
EP1648995A2 (en) 2006-04-26
WO2005010141A2 (en) 2005-02-03
CA2531492A1 (en) 2005-02-03
NO20060400L (no) 2006-03-27

Similar Documents

Publication Publication Date Title
US7956165B2 (en) Compositions and methods for purifying and crystallizing molecules of interest
JPH05508701A (ja) 被分析物に結合するリガンドの同定方法
WO2005010141A2 (en) Compositions for purifying and crystallizing molecules of interest
CN118804983A (zh) 含Fc分子的制造方法
JPH03197500A (ja) Hplcアビジン・アフィニティー樹脂
CN107073093A (zh) 亲和蛋白及其用途
WO2006085321A2 (en) Compositions and methods for purifying and crystallizing molecules of interest
JP2022501063A5 (cg-RX-API-DMAC7.html)
CN114380907B (zh) 靶向cmtm6的纳米抗体及其制备方法和应用
EP4685231A1 (en) Helicobacter pylori fucosyltransferase mutant
JP6171331B2 (ja) Fc結合性タンパク質の精製方法および定量方法
JP2002058479A (ja) 構造認識アミノ酸配列の取得方法
CN112239504A (zh) 一种针对pd-l1的纳米抗体及其应用
EP1541588A1 (en) Single chain antibody and utilization thereof
WO1997013522A1 (en) Generating d-peptides: methods and compositions
JPH03259093A (ja) 癌関連ヒト由来ガラクトース転移酵素に特異的なモノクローナル抗体、それを産生するハイブリドーマ及びそれを用いた検体中の癌関連ヒト由来ガラクトース転移酵素の測定方法
AU2006200118A1 (en) Compositions and Methods for Purifying and Crystallizing Molecules of Interest
CN107987167B (zh) 一种RNA聚合酶II转录亚基37e介体的单克隆抗体及其应用
WO2024091120A1 (en) N-terminal protein modification
JP4361578B2 (ja) コンドロイチン硫酸リアーゼiiに対するモノクローナル抗体
CN119504984A (zh) Fc片段、重组载体、重组细胞和融合抗原及其制备方法
JPH06125784A (ja) モノクローナル抗体,ハイブリドーマ,その製造法および用途
JP4090487B2 (ja) コンドロイチナーゼabcに対するモノクローナル抗体
CN121895439A (zh) 靶向aav8和aav9的结合分子及其用途
CN120283055A (zh) 异多聚体蛋白质的制造方法、蛋白质、核酸、表达载体、转化体、以及蛋白质的制造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090422